AbbVie and Simcere Zaiming Partner on Trispecific Antibody for Multiple Myeloma in $1.055B Deal

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group, announced on Wednesday a licensing option agreement to develop a new drug targeting multiple myeloma that is being studied in phase I clinical trials in patients with relapsed or refractory myeloma in China and the United States.

According to a statement, SIM0500 is a trispecific humanized antibody directed against the GPRC5D, BCMA and CD3 genes. Until now, Simcere Zaiming had been in charge of its development through a technological platform of polyspecific antibodies for T lymphocyte capture.

Simcere Zaiming will receive an upfront payment from AbbVie and will be eligible to receive option rights and milestone payments of up to $1.055 billion

“We hope that our partnership has the potential to help address important unmet medical needs for people with multiple myeloma,” AbbVie said.

This molecule features a low affinity/high targeting CD3 recruitment arm and binding sites for both tumor antigens: G protein-coupled receptor, group 5, member D (GPRC5D) and B cell maturation antigen (BCMA). SIM0500 has been shown to produce strong T cell cytotoxicity against multiple myeloma cells through a combination of several anti-tumor effects.

Representatives of both companies have welcomed the agreement reached. In this regard, Renhong Tang , PhD and CEO of Simcere Zaiming, has pointed out that the company is “ delighted ” with its partnership with AbbVie and has confidence in the work that will allow them to advance in the clinical development of SIM0500.

SIM0500 has been shown to produce strong cytotoxicity in T lymphocytes against myeloma cells thanks to a combination of several antitumor effects.

“We expect that our partnership with Simcere Zaiming to develop this novel trispecific antibody has the potential to help address important unmet medical needs for people with multiple myeloma,” added Mariana Cota Stirner, vice president and therapeutic area head of hematology at AbbVie.

The companies said Simcere Zaiming will receive an upfront payment from AbbVie and will be eligible to receive option rights and milestone payments of up to $1.055 billion, as well as milestone royalties on net sales outside of China. AbbVie is eligible to receive tiered royalties on net sales within China.

__

(Featured image by CDC via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us